Italia markets open in 6 hours 20 minutes

Valneva SE (VLA.PA)

Paris - Paris Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
4,6540-0,1140 (-2,39%)
Alla chiusura: 05:38PM CEST
Schermo intero
Chiusura precedente4,7680
Aperto4,7800
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno4,6080 - 4,7800
Intervallo di 52 settimane4,4200 - 18,9200
Volume258.922
Media Volume388.107
Capitalizzazione666,35M
Beta (5 anni mensile)1,01
Rapporto PE (ttm)5,97
EPS (ttm)0,7800
Prossima data utili04 mag 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A10,10
  • GlobeNewswire

    Valneva Reports Full Year 2022 Results and Provides Corporate Updates

    Total revenues of €361.3 million in 2022 compared to €348.1 million in 2021 Driven by product sales of €114.8 million (82.3% increase compared to 2021), including €85.2 million of travel vaccine sales and €29.6 million of COVID-19 vaccine sales€246.5 million of Other Revenues, primarily driven by revenue recognition related to previous COVID-19 vaccine supply agreements Strong cash position of €289.4 million at December 31, 2022 Raised over €190 million in equity: €102.9 million of gross proceed

  • GlobeNewswire

    VALNEVA - Declaration of shares and voting rights - February 28, 2023

    VALNEVA Declaration of shares and voting rightsFebruary 28, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: March 6, 2023 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this change wa

  • GlobeNewswire

    Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001

    Saint-Herblain (France), March 2, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced additional data from remaining clinical studies and an update on regulatory submissions for its inactivated COVID-19 vaccine, VLA2001. As previously announced, Valneva will not invest in further development of the vaccine, in the absence of a new partnership1. It is, however, completing remaining clinical studies and submissions as agreed with regulators. On Febru